Close Menu

technology development

The companies will combine the Binx io diagnostic platform with Sherlock Bio's CRISPR technology to create an easy-to-use rapid test for the point of care.

The firm touts a new hybridization probe design, which it says will enable small, focused panels that reduce sequencing costs and assay time.

In a study published last month, Mammoth demonstrated the technology's sensitivity, specificity, and speed compared to PCR-based COVID-19 testing.

French startup SeqOne has adapted its sequencing data-analysis platform to support a new method for high-throughput processing of coronavirus tests in its home country.

The German hospital will build interpretation and reporting on the PierianDx Clinical Genomics Workspace for two Illumina assays.

Lexogen did not disclose the funding amount, but said it was one of €16 million ($17.4 million) in awards from the Austria Research Promotion Agency.

Genomics England has slashed storage costs by migrating to a new file system, while NIH's All of Us research program is seeking savings from a cloud environment.

Illumina, LabCorp, and Providence healthcare will join the effort to collect COVID-19 patient samples in the US for immune cell receptor sequencing.

The deal is part of a wider collaboration between the companies to develop molecular diagnostic tests using their respective platforms.

Founded by former Inteliquet CEO Carla Balch, the firm is building on visualization technology to help physicians incorporate MDx testing into their practice. 

Pages

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.